Tuesday, April 23, 2024
This test joins the AD-Detect™ portfolio of blood tests, which includes assessments for p-tau181, amyloid beta (AB) proteins, Apolipoprotein E (ApoE) isoforms, and plasma testing for patients with cognitive impairment. Patients can provide blood samples for testing at any of Quest's 2,000 patient service centers in the United States with a physician's order, starting April 26, 2024.
Quest Diagnostics aims to expand access to innovative dementia diagnostic solutions for patients and providers. The addition of p-tau217 to its neurology testing portfolio enhances the company's comprehensive offering. Kathleen Valentine, Vice President and General Manager of Neurology at Quest Diagnostics, emphasizes the company's commitment to improving Alzheimer's Disease diagnosis and risk assessment.
While amyloid PET imaging has been a traditional method for AD diagnosis, it is expensive and invasive. In contrast, Quest's AD-Detect™ blood tests offer a more accessible alternative for patients and providers.
The evolving landscape of AD assessment and diagnosis, emphasizing the potential of p-tau217, especially when combined with cognitive test results, to aid in early diagnosis and assessing patients with cognitive impairment.
With nearly 7 million Americans affected by Alzheimer's Disease, new blood tests offer promise for identifying individuals at risk before symptoms appear. This aligns with the belief of 77% of physicians surveyed, who anticipate that new therapies will transform Alzheimer's into a manageable chronic disease.
As a leader in neurology, Quest Diagnostics remains dedicated to advancing laboratory services to aid in evaluating patient risk of Alzheimer's Disease and other dementias. Leveraging its extensive network, Quest is uniquely positioned to facilitate blood specimen collection and provide advanced laboratory testing on a national scale.
Source: prnewswire.com
